Tenaya Therapeutics
Biotechnology company
- 101-200 employees
- Healthcare
- B2B
- Manufacturing
- Biology
- Oyster Point, South San Francisco, CA
Jump to section
Company mission
To discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease.
Our take
Heart disease has long been the leading cause of death in the world. Tenaya Therapeutics works to discover, develop and delivery curative therapies that address the underlying causes of cardiovascular diseases.
Tenaya has carved out a unique position in the market, both with its impressive founding body of Gladstone Institutes notoriety, and with its multi-pronged approach in an attempt to increase the possibility of solving the different types of problems that can lead to heart disease and failure. This three-angle approach includes gene therapy, cellular regeneration and precision medicine.
Recent funding will accelerate its lead gene therapy program towards clinical studies whilst advancing development of new programs. Tenaya will invest into building on existing drug discovery and development capabilities across its three platforms.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- State-of-the-art, built-to-suit office and lab space, part of a larger cluster of biotech companies, with amenities that include a bowling alley and onsite gym
- Stock options
- Excellent medical and non-medical benefits
- Paid vacation, sick time, and holidays
Funding (last 2 of 3 rounds)
Mar 2021
$106m
SERIES C
Oct 2019
$92m
SERIES B
Total funding: $248m
This company has top investors
Leadership
Benoit Bruneau
(Co-founder)Currently acts as Director of Gladstone Institute of Cardiovascular Disease. Previously served as a Scientist for The Hospital for Sick Children.
Bruce Conklin
(Co-founder)Currently acts as Deputy Director for Innovative Genomics Institute and as Investigator for Gladstone Institutes. Previously worked as a Consultant for iPierian Inc and as an Advisor for California Academy of Sciences.
Sheng Ding
(Co-founder)Currently acts as Institute Director for Global Health Drug Discovery Institute, Professor and Dean of School of Pharmaceutical Sciences, Tsinghua University, and Senior Investigator for Gladstone Institutes. Previously co-founded Fate Therapeutics, Vivace Therapeutics, and Stemgent.
Faraz Ali
(CEO, not founder)Previously served as Chief Business Officer for REGENXBIO, Vice President of Global Commercial Development and External Affairs for bluebird bio, and Senior Director of US Marketing and Strategic Planning for Sanofi Genzyme.